ASP Isotopes Forms 80/20 HALEU Production Joint Venture with Necsa in South Africa

Key highlights

• Joint venture ownership split at 80% for Quantum Leap Energy and 20% for Necsa
• Commercial-scale HALEU production facility to be located at the Pelindaba site in South Africa
• Project supported by existing offtake agreements with advanced reactor developer TerraPower
• Regulatory approval received in July 2026 for source material and equipment transport
• Quantum Leap Energy responsible for operations and the arrangement of project capital

What Is the Partnership?

Quantum Leap Energy LLC, a wholly-owned subsidiary of ASP Isotopes, has finalized a binding commercial framework with the Nuclear Energy Corporation of South Africa SOC Limited to develop and operate High-Assay Low-Enriched Uranium (HALEU) facilities. Under the 80/20 ownership structure, Quantum Leap Energy will lead operational management and capital procurement for the project. The venture is designed to advance through two stages: the construction of a test bench and the eventual commissioning of a commercial-scale production facility at Necsa's Pelindaba site. This agreement formalizes a relationship that began with a memorandum of understanding in late 2024.

Partner Profile

Necsa serves as the statutory nuclear energy institution for the Republic of South Africa, headquartered at the Pelindaba nuclear research center. The organization manages the 20MW SAFARI-1 research reactor and possesses over six decades of experience in nuclear operations, safeguards, and regulatory compliance. Beyond providing site access, Necsa will contribute critical licensing and regulatory support to the joint venture. The partnership also anticipates an engineering, procurement, and construction arrangement, granting the project direct access to Necsa's specialized engineering capabilities and existing nuclear platform.

What It Unlocks

• Secures a physical location at South Africa's premier nuclear research center for enrichment activities
• Utilizes established offtake agreements with TerraPower to guarantee future revenue streams
• Leverages a $22.0 million credit facility from TerraPower previously secured for HALEU plant construction
• Expands technical reach through existing research agreements with Texas A&M and the University of Bristol
• Facilitates a highly efficient route to market by combining proprietary enrichment tech with licensed infrastructure

Financial and Market Context

ASP Isotopes operates within the specialty chemicals and nuclear materials sector with a reported annual revenue of $23.85 million. The company has communicated long-term financial targets, including a goal of generating over $300 million in annual EBITDA by 2031. Currently, the stock shows technical oversold characteristics with a Relative Strength Index (RSI) of 22.8, following a quarter-to-date price decline of 54.9%. The joint venture aligns with the company's broader expansion strategy, which includes the pending merger of its Noble Africa LLC subsidiary with ENDRA Life Sciences expected in the fourth quarter of 2026.

Management commentary

“The world needs new, reliable and secure sources of advanced nuclear fuel, and South Africa is well placed to provide them. Through this partnership with Quantum Leap Energy, Necsa will bring its decades of experience in nuclear operations, safeguards and regulatory compliance to creating a trusted new source of commercial HALEU supply.”

“This agreement demonstrates real commercial progress and brings us one step closer to enrichment. We are proud to be working alongside Necsa, whose nuclear site, infrastructure and expertise no other partner could replicate.”

ASP Isotopes Inc. · financial snapshot

Share price	$2.07
Market cap	$317M
Revenue (annual)	$24M
1-month price change	-35.11%
Sector	Basic MaterialsSpecialty Chemicals

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.